Core Viewpoint - Monte Rosa Therapeutics (GLUE) has seen a 22.5% increase in share price over the past four weeks, closing at $5.01, with a potential upside indicated by Wall Street analysts' mean price target of $16.14, suggesting a 222.2% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $3.98, where the lowest estimate of $10 indicates a 99.6% increase, and the highest estimate suggests a 299.2% surge to $20 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about GLUE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - Over the last 30 days, three earnings estimates for the current year have been revised higher, leading to a 56.6% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - GLUE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13]

Shares of Phathom Pharmaceuticals, Inc. (PHAT) have gained 184.1% over the past four weeks to close the last trading session at $8.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.50 indicates a potential upside of 107.4%.The mean estimate comprises eight short-term price targets with a standard deviation of $8.09. While the lowest estimate of $5 indicates a 44% decline f ...

The RealReal (REAL) closed the last trading session at $5.71, gaining 13.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.10 indicates a 76.9% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $3.09. While the lowest estimate of $7 indicates a 22.6% increase from the current price level, the most optimistic analyst expects ...

Shares of ZipRecruiter, Inc. (ZIP) have gained 43.4% over the past four weeks to close the last trading session at $6.25, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8 indicates a potential upside of 28%.The mean estimate comprises five short-term price targets with a standard deviation of $1.87. While the lowest estimate of $6 indicates a 4% decline from the current price ...

Core Viewpoint - Sagimet Biosciences Inc. (SGMT) shares have increased by 70.6% in the past four weeks, closing at $5.56, with a mean price target of $29.86 indicating a potential upside of 437.1% according to Wall Street analysts [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $20.44, indicating variability among analysts; the lowest estimate suggests a 10.1% decline, while the highest predicts a surge of 1105% to $67 [2] - Analysts' consensus on price targets is often questioned, as they may not accurately reflect the stock's future price movements [3][7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Group 2: Earnings Estimates and Market Sentiment - Analysts are optimistic about SGMT's earnings prospects, as indicated by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 26.4% over the past month, with four estimates increasing and no negative revisions [12] - SGMT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]

Group 1 - HubSpot (HUBS) closed at $609.40, with a 1.1% gain over the past four weeks, and a mean price target of $763.91 indicating a 25.4% upside potential [1] - The mean estimate consists of 32 short-term price targets with a standard deviation of $66.58, where the lowest estimate is $645 (5.8% increase) and the highest is $930 (52.6% increase) [2] - Analysts show strong agreement on HUBS's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - The Zacks Consensus Estimate for HUBS has increased by 49.9% over the past month, with 13 estimates going higher and no negative revisions [12] - HUBS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator, the direction of price movement it implies appears to be a good guide for potential gains [13]

Core Viewpoint - Vigil Neuroscience, Inc. (VIGL) has seen a significant stock price increase of 225.6% over the past four weeks, with a mean price target of $10 indicating a further upside potential of 26.9% [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $5.29, indicating variability among analysts; the lowest estimate suggests a 1.5% increase to $8, while the highest predicts a surge of 179.2% to $22 [2] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases; the Zacks Consensus Estimate for the current year has risen by 7.3% over the past month with three estimates increasing and no negative revisions [11][12] - VIGL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a solid potential upside [13]

Shares of QuinStreet (QNST) have gained 8.1% over the past four weeks to close the last trading session at $16.06, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $28.40 indicates a potential upside of 76.8%.The mean estimate comprises five short-term price targets with a standard deviation of $5.90. While the lowest estimate of $19 indicates an 18.3% increase from the current p ...

2025年06月08日 证券研究报告 | 美股市场速览 标普500重回6000，中小盘全面跑赢 行业研究·海外市场专题 美股 中性·维持 证券分析师：王学恒 证券分析师：张熙，CFA 010-88005382 0755-81982090 wangxueh@guosen.com.cn zhangxi4@guosen.com.cn S0980514030002 S0980522040001 请务必阅读正文之后的免责声明及其项下所有内容 数据速览 价格走势：市场震荡向上，中小盘全面跑赢 本周，美股震荡向上，标普500涨1.5%，纳斯达克涨2.2%。 风格：小盘成长（罗素2000成长+4.0%）>小盘价值（罗素2000价值+2.4%）>大盘成长（罗素1000成长+2.0%）>大盘价值（罗素1000价值+1.0%）。 17个行业上涨，6个行业下跌，1个基本持平。涨幅居前的行业有：半导体产品与设备（+4.7%）、媒体与娱乐（+3.5%）、零售业（+3.0%）、消费者服务 （+2.5%）、技术硬件与设备（+2.2%）；跌幅居前的行业有：汽车与汽车零部件（-13.5%）、家庭与个人用品（-3.7%）、公用事业（-1.0%）、 ...

Shares of Silence Therapeutics PLC Sponsored ADR (SLN) have gained 52% over the past four weeks to close the last trading session at $5.41, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.50 indicates a potential upside of 556.2%.The mean estimate comprises six short-term price targets with a standard deviation of $23.86. While the lowest estimate of $3 indicates a 44.6% dec ...